In the fall of 1957, a young scientist, Andrew Schally, joined neuroendocrinologist Roger Guillemin’s lab at Baylor College of Medicine in Houston. The two seemed to have a lot in common: Both were émigrés from Europe. Both had moved to the United States after finishing PhDs in physiology in Montreal. Moreover, both were on the same side of a controversy in endocrinology about what controls the pituitary gland.

Although known as the master gland because it secretes hormones that control other glands, the pituitary releases nothing until it receives the right stimulus. At the time, most endocrinologists thought that the brain structure called the hypothalamus dispatched nerve impulses that spurred the pituitary to spill hormones into the bloodstream. But Guillemin and Schally were among the few scientists who held that molecular messengers, or factors, produced by the hypothalamus were responsible. Some circumstantial evidence supported that alternative, but “the proposition would remain speculative until direct evidence for the existence of specific hypothalamic chemotransmitters controlling release of pituitary hormones could be demonstrated,” Schally wrote. By joining forces, he and Guillemin intended to find that evidence.

Rotating human brain: hypothalamus (red), amygdala (green), hippocampus (blue), pons (gold), pituitary gland (pink)
Courtesy of lifesciencedb

Their meeting was not the beginning of a beautiful friendship, however. The two fell out, and in 1962 Schally left to start a competing lab at the Veterans Administration Hospital in New Orleans. The pair became implacable scientific enemies and remained so until the ends of their lives. “They hated each other for a very long time,” says Guillemin’s colleague and friend Tony Hunter, a cell and molecular biologist at the Salk Institute for Biological Studies.

Still, tracking down the elusive hypothalamic factors required heroic amounts of lab work, and the rancorous rivalry between the scientists may have been beneficial because it “produced a lot of motivation and led to greater efforts,” as one of their contemporaries put it. In any case, after racing each other for 7 years, the scientists crossed the finish line almost simultaneously. Both teams reported in 1969 that they had synthesized one of the factors, thyrotropin-releasing hormone (TRH), and worked out its chemical structure. Over the next few years, the researchers repeated the feat for two other hypothalamus-produced factors—gonadotropin-releasing hormone (GnRH) and growth hormone–inhibiting hormone (GHIH), also known as somatostatin. The results earned them the 1975 Albert Lasker Basic Medical Research Award and the 1977 Nobel Prize in physiology or medicine.

Schally and Guillemin are two of the researchers who have won Lasker awards for studying hormones—messengers that travel through the blood and exert widespread effects—or locally acting molecules known as prostaglandins. Some Lasker winners expanded the roster of known hormones and elucidated the often-surprising ways in which many of those molecules induce their effects. Other winners identified prostaglandins and uncovered their diverse and unexpected influences on the body. Those discoveries also proved to be a boon for medicine. Many of us need drugs that directly or indirectly emerged from those findings, including prednisone, growth hormone, and the asthma treatment montelukast.

Masters of the Master Gland
Guillemin and Schally weren’t just racing each other. Several other scientists tried to isolate the hypothalamic hormones in the 1950s and 1960s, but the obstacles were enormous. The molecules are vanishingly rare in the hypothalamus—a tiny part of the brain—with only crude techniques available at the time to sift out the factors.

Roger Guillemin continued to study hypothalamic hormones after he moved to the Salk Institute in 1970.
Courtesy of Salk Institute

Schally and Guillemin adopted what Hunter calls a grind-and-purify approach to extract the molecules from vast amounts of animal brain tissue. To eke out 1 milligram of TRH, Guillemin and colleagues needed more than 300,000 sheep hypothalami, obtained from slaughterhouses. Schally’s group used a similar number of the structures from pigs. The researchers essentially turned their labs into factories for processing and chemically analyzing the tissue. They brought in teams that included chemists, endocrinologists, and physiologists. “Roger drove his people hard,” Hunter says. “He didn’t want to lose.” Schally was equally committed. “He had a goal and would do whatever was needed to reach that goal,” says his friend and colleague Medhi Wangpaichitr, a cell biologist at the University of Miami Miller School of Medicine.

Andrew Schally, shown here in his lab at Tulane University, performed science on an almost industrial scale to isolate hormones from the hypothalamus. 
Courtesy of Tulane University

By the late 1960s, though, other scientists worried about the teams’ lack of results. The National Institutes of Health nearly pulled the researchers’ funding. Schally and Guillemin silenced the skeptics with their revelations about TRH. Scientists now know that the hypothalamus produces six molecules that orchestrate release of hormones by the pituitary. TRH, for instance, prods the pituitary to secrete thyroid-stimulating hormone, which in turn spurs the thyroid to release the metabolic hormone thyroxine. Guillemin and Schally provided the first glimpse of the complex control system that helps regulate levels of pituitary hormones in the body.

A Shot in the Dark
The U.S. military received disturbing intelligence in 1941: The Germans were importing huge quantities of cattle adrenal glands from Argentina and planned to produce an elixir to improve the performance of pilots at high altitude. The news proved false, but it helped spark a U.S. government program to synthesize hormones from the adrenal gland and test them for medical uses.

Although the program yielded no new treatments by the end of the war, it was a boon for one of its scientific leaders, biochemist Edward Kendall of the Mayo Clinic. The knowledge that researchers gained through the program allowed them for the first time to synthesize large quantities of cortisone, an adrenal compound that Kendall was keen to test. In 1948, he teamed with Mayo Clinic rheumatologist Philip Hench and colleagues and began injecting the newly available cortisone into people with rheumatoid arthritis, a sometimes-crippling condition in which the immune system attacks the joints. The recipients’ symptoms improved dramatically—after treatment, one patient who had been in a wheelchair could walk. For that work and other research to understand the adrenal hormones, Kendall and Hench earned the 1949 Albert Lasker Clinical Medical Research Award and the 1950 Nobel Prize in physiology or medicine.

Image of a human kidney with highlighted adrenal gland and hormones floating in blood vessels
Courtesy of ScienceSource

The rumor that the Germans might squeeze a beneficial compound out of the adrenal glands was plausible. Starting in the 1930s, Kendall and several other biochemists, including fellow Nobel laureate Tadeus Reichstein of the University of Basel, had been isolating and naming an assortment of molecules produced by the glands. Like Guillemin and Schally, Kendall needed large amounts of animal tissue for the work—his lab went through more than 400 kilograms of cow adrenal glands per week. Also using a grind-and-purify approach, he identified compounds he called A, B, E, and F. He thought that compound E, cortisone, held the most promise as a treatment.

Hench found a target. He had noticed that patients with rheumatoid arthritis often improved after developing liver conditions that caused jaundice. The symptoms also often eased in pregnant women. Hench concluded that both groups were producing a molecule he called substance X that alleviated the symptoms. Kendall and Hench decided to test whether compound E and substance X were the same. As Hench admitted, “we had no firm conviction, only the hope, that this compound might be substance X.” The researchers took a flier, but their results proved them right.

Edward Kendall (second from right) and Philip Hench (far right) meet with colleagues in 1949, the year after they began testing cortisone in patients.
Courtesy of Mayo Foundation for Medical Education and Research

Within a year, doctors throughout the United States were treating patients with cortisone. Kendall and Hench didn’t understand how it works, however. Researchers have since learned that cortisone itself is almost inert. Once the molecule is in the body, the liver converts it into an active hormone, cortisol, which was Kendall’s compound F. In turn, cortisol quells inflammation and induces various other effects.

Kendall and Hench’s findings were important because they showed that it was possible to target the immune system to treat a disease, says pediatric endocrinologist Perrin White of the University of Texas Southwestern Medical Center. Cortisol, part of the drug class known as corticosteroids, remains a treatment for rashes, allergies, and other immune-related conditions. But the results made a bigger impact by spawning a profusion of new corticosteroids that “are a major part of medicine” in areas such as oncology, rheumatology, and endocrinology, White says. Those drugs include prednisone, dexamethasone, prednisolone, and triamcinolone. “All of these compounds are based on cortisol,” he says.

Pass It On
One scientist’s effort to understand another adrenal hormone, epinephrine, aka adrenaline, transformed our understanding of how hormones work and sparked research that led to one-third of the drugs in use today. While probing epinephrine’s effects on the liver, biochemist Earl Sutherland of Washington University chanced on the molecule cyclic AMP (cAMP), which serves as a second messenger, disseminating the hormone’s directives inside target cells. The revelation that some hormones communicate through intermediaries earned him the 1970 Albert Lasker Basic Medical Research Award and the 1971 Nobel Prize in physiology or medicine.

While studying the effects of epinephrine, Earl Sutherland chanced on a new mechanism of hormone communication.
Courtesy of Vanderbilt University School of Medicine

The discovery of cAMP came out of the blue, says protein chemist Susan Taylor of the University of California, San Diego. “It’s ubiquitous in every cell, but nobody knew about it before Sutherland identified it.” The implications of the finding extend well beyond hormone research, adds pharmacologist Laurence Brunton, also of UC San Diego. “It has permeated so many different fields.”

When we are under stress, the adrenal glands pump out epinephrine, which orchestrates various responses that help us cope with a dangerous situation. One effect is to stimulate the liver to release some of the glucose it has cached as glycogen, thus providing a jolt of cellular fuel. In the 1950s, Sutherland began studying the mechanism of that response in samples of animal liver tissue. He noticed that epinephrine no longer had any effect if he ground up and centrifuged the tissue, a procedure that removed the cellular debris. He assumed that the cellular detritus contained a molecule that passed on the hormone’s message, and he and his colleague Theodore Rall soon identified it as cAMP.

At the time, researchers knew little about how proteins triggered cellular reactions. The idea was “the hormone was the first messenger, and it did something mysterious,” Brunton says. But Sutherland showed that, upon arriving at the cell membrane, a hormone stimulates formation of cAMP inside the cell, which then activates enzymes that instigate the appropriate responses. Many hormones besides epinephrine, including calcitonin, glucagon, luteinizing hormone, and follicle-stimulating hormone, rely on cAMP or other second messengers. cAMP participates in “just about every cellular biochemical process you can think of,” says pulmonologist Marc Peters-Golden of the University of Michigan Medical School. It also relays messages in bacteria and other organisms that don’t have hormones. “It’s a universal second messenger,” Taylor says.

Although it wasn’t apparent when Sutherland won the Lasker, his discovery changed medicine. As researchers delved into cAMP’s mechanism, they found that hormones such as epinephrine trigger cells to produce the molecule by stimulating the G protein–coupled receptors (GPCRs), a huge family of transceivers on the cell surface that are instrumental for vision, taste, immunity, nerve transmission, and other functions. Mutant GPCRs also are implicated in many diseases, including heart disease, diabetes, and cancer. About one-third of current medications affect GPCRs, making them the largest family of drug targets. “The impact has been enormous,” Peters-Golden says.

The Synthesizer
After finishing his PhD at the University of California, Berkeley, in 1938, biochemist Choh Hao Li needed a job. But he was looking for work during the Great Depression, one of the worst job markets in history. Even though he knew little about hormones, Li signed on at a Berkeley institute investigating the biology of pituitary hormones. Over the next few decades, Li applied his chemistry talents to isolate, sequence, and ultimately synthesize several of those hormones, earning him the 1962 Albert Lasker Basic Medical Research Award.

Transmission electron micrograph of a growth hormone-producing cell from the pituitary gland
Courtesy of ScienceSource

“The whole notion of being able to elucidate the structure of a hormone and then synthesize the molecule has revolutionized endocrinology during the last 80 years,” says endocrinologist Shlomo Melmed of Cedars-Sinai Health Sciences University. Li was one of the “genius chemists” who figured out how to do it, he says.

A gifted chemist, Choh Hao Li figured out how to synthesize growth hormone and other hormones.
Courtesy of Regents of the University of California

Li started small, beavering away in a tiny lab in his institute’s basement. But he soon became one of the foremost biochemists in his field, in part because of “his resourcefulness and a capacity to concentrate his effort,” a former graduate student wrote. Li and colleagues determined the amino acid sequences of luteinizing hormone, follicle-stimulating hormone, and adrenocorticotropic hormone, which stimulates the adrenal glands to release cortisol. His group also synthesized all those hormones. But Li’s most influential work involved growth hormone. He and colleagues first purified the cattle version of the hormone in 1944. By 1970, they had worked out how to synthesize the human version—“a remarkable feat,” Hunter says.

Li’s results made researchers’ lives much easier, Melmed says. “Until the mid-1970s, it was very difficult to measure hormones,” he says. Scientists relied on bioassays, which usually involved injecting a blood or tissue sample that might contain the hormone into an animal and then observing the results. When researchers figured out how to synthesize hormones, however, they could develop more specific assays and delve deeper into the effects of the molecules.

The ability to synthesize hormones also led to improved treatments for conditions such as short stature due to growth hormone deficiency. In the 1950s, doctors began dosing extremely short children with growth hormone isolated from the pituitary glands of cadavers. The treatment was expensive, however, and because of infectious brain contaminants, it caused a fatal neurological disease in some patients. Once researchers could make human growth hormone, they could devise ways to manufacture it industrially. The first synthetic version of human growth hormone, produced by genetically modified bacteria, reached the market in 1985.

Signals That Stay Close to Home
Seniors who take a daily aspirin to prevent heart attacks, patients with asthma, pregnant women struggling to give birth, and people with the lethal condition pulmonary arterial hypertension (high blood pressure in lung arteries) are just some of the beneficiaries of the work by the winners of the 1977 Albert Lasker Basic Medical Research Award. Biochemists Sune Bergström and Bengt Samuelsson of the Karolinska Institute and pharmacologist John Vane of Wellcome Research Laboratories made pioneering discoveries about prostaglandins, potent molecules that trigger various effects in the body. The scientists isolated prostaglandins, showed how our cells synthesize them, and revealed some of their important physiological consequences. For those findings, the trio also shared the 1982 Nobel Prize in physiology or medicine.

The 1977 Lasker Awards ceremony, from left to right: Michael DeBakey, Mary Lasker, John Brademas, and Sune Bergström

Hormones circulate through the blood, stay active for a relatively long time, and cause far-flung effects. Prostaglandins, by contrast, “are found in very small amounts and are evanescent,” says pharmacologist Garret FitzGerald of the University of Pennsylvania Perelman School of Medicine. Prostaglandins also act within or near the cells that produce them. Despite their limited range and short lifespan, the molecules have “a remarkably diverse biological impact,” FitzGerald says.

Researchers had seen hints of that impact as far back as the 1930s. For instance, one scientist found that human seminal fluid contained a substance that decreased blood pressure when injected into animals. Bergström began tracking down the molecules behind such effects in 1945, when a colleague suggested they analyze some sheep prostate secretions that he had been storing for nearly a decade. The researchers’ experiments suggested that something in the secretions triggered biological effects. Encouraged, Bergström began chemically analyzing many prostate glands from sheep. By 1957, he and colleagues had isolated the first two prostaglandins. By 1962, they had nabbed four more.

Bengt Samuelsson

Samuelsson first collaborated with Bergström to decipher the chemical structures of the prostaglandins they had identified. Once Samuelsson started his own lab in the early 1960s, he decided to figure out how the body makes the molecules. He and colleagues assembled a family tree showing the relationships among various prostaglandins and their molecular predecessors. In 1979, his lab also discovered medically important relatives of prostaglandins known as leukotrienes, whose effects include triggering airway narrowing in asthma.

Vane, meanwhile, uncovered a clinically useful prostaglandin, prostacyclin, that inhibits blood clotting and stimulates blood vessels to relax. His team also determined that aspirin and other nonsteroidal anti-inflammatory drugs thwart prostaglandin synthesis, offering an explanation for how those widely used medications work. Vane’s contribution to prostaglandin research “was very important. It brought us to their potential role in physiology,” FitzGerald says.

Sir John Vane (left) and Salvador Moncada at the Wellcome Laboratories at Beckenham, Kent
Courtesy of Wellcome Trust

Researchers have capitalized on those discoveries to develop a slew of treatments and preventives. Prostacyclin is one therapy for patients with pulmonary arterial hypertension. The drugs misoprostol and dinoprostone induce labor. The connection between some prostaglandins and blood clotting also led to the widespread use of low-dose aspirin to prevent heart attacks. Asthma medications such as montelukast and zileuton stymie leukotrienes. As FitzGerald notes, all those applications stem from “the happy convergence between an English physiologist and structural chemists from the Karolinska Institute.”

Scientists continue to build on the legacies of those nine Lasker winners. Before Schally’s death, for example, he and colleagues investigated another hypothalamic hormone, growth hormone–releasing hormone (GHRH). The researchers have synthesized new molecules that block GHRH or stimulate the same effects. Animal studies showed that some of those molecules conferred benefits against cancer and a rodent version of Alzheimer’s disease. Wangpaichitr says they are hoping to begin a clinical trial of one of the compounds soon. That research, which Schally launched, illustrates one quality that served him well throughout his career: “He had a global vision,” Wangpaichitr says.

By Mitchell Leslie